About One-Third of People With Cannabis-Induced Psychosis Later Develop Schizophrenia

Systematic review and meta-analysis searching Medline, Embase, Web of Science, Google Scholar, and PsychInfo through January 2025. Included studies reporting on patients with cannabis-induced psychosis who were followed for subsequent schizophrenia spectrum or bipolar disorder diagnoses. Quality assessed using modified Newcastle-Ottawa scale. Random-effects meta-analyses calculated pooled prevalence; meta-regressions identified predictors.

Distinguishing cannabis-induced psychosis from the onset of a primary psychotic disorder is one of the most consequential diagnostic challenges in psychiatry. This meta-analysis quantifies the stakes: about a third of cannabis-induced psychosis cases may actually be the first presentation of schizophrenia spectrum illness. That finding has direct implications for how aggressively clinicians should monitor and treat patients after a cannabis-induced psychotic episode.

This meta-analysis strengthens the evidence linking cannabis to psychotic disorders (connecting to RTHC-00163, RTHC-00193, RTHC-00201, RTHC-00202, RTHC-00203, RTHC-00215). The ~34% conversion rate to schizophrenia is higher than the rate reported for psychosis from other substances, suggesting something specific about the cannabis-psychosis relationship rather than a generic substance-triggered vulnerability. The placental marker study (RTHC-00254) adds a possible prenatal dimension to this story.

Observational studies with variable follow-up periods — some patients may convert after the study period ends, meaning these rates could be underestimates. Diagnosis of cannabis-induced psychosis vs. primary psychotic disorder is inherently difficult at first presentation. Studies could not control for all confounders (genetics, polysubstance use, premorbid function). Publication bias may affect results.